 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || YH004 / Biocytogen
Enrollment open, Metastases: Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 7, 2023
P1, N=38, Recruiting, Sponsor: Eucure (Beijing) Biopharma Co., Ltd
Not yet recruiting --> Recruiting
- || Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, YH004 / Biocytogen
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy (clinicaltrials.gov) - Sep 7, 2023
P1, N=8, Completed, Sponsor: Eucure (Beijing) Biopharma Co., Ltd
Not yet recruiting --> Recruiting Recruiting --> Completed | N=80 --> 8 | Trial completion date: Jun 2024 --> Jul 2023 | Trial primary completion date: Jan 2024 --> Jul 2023
- || YH004 / Biocytogen
New P1 trial, Metastases: Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 4, 2022
P1, N=38, Not yet recruiting, Sponsor: Eucure (Beijing) Biopharma Co., Ltd
- ||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, YH004 / Biocytogen
Enrollment open, Trial initiation date, Metastases: Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy (clinicaltrials.gov) - Dec 22, 2021
P1, N=80, Recruiting, Sponsor: Eucure (Beijing) Biopharma Co., Ltd
Recruiting --> Completed | N=80 --> 8 | Trial completion date: Jun 2024 --> Jul 2023 | Trial primary completion date: Jan 2024 --> Jul 2023 Not yet recruiting --> Recruiting | Initiation date: Sep 2021 --> Dec 2021
- ||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, YH004 / Biocytogen
New P1 trial, Metastases: Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy (clinicaltrials.gov) - Sep 10, 2021
P1, N=80, Not yet recruiting, Sponsor: Eucure (Beijing) Biopharma Co., Ltd